5.2 Investigational Device Exemptions (IDE) & Device Classification (21 CFR Part 812)

Investigational Device Exemptions (IDE) & Device Classification (21 CFR Part 812)

Medical Device Classification Framework

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), medical devices are regulated based on their level of risk to patients. The Food and Drug Administration (FDA) groups medical devices into three distinct regulatory classes. The level of regulatory control increases from Class I to Class III, ensuring that human subjects and the public are protected while allowing for technological innovation.

Class I Devices: Low Risk

Class I devices present the lowest potential risk to the patient or user. These devices are subject only to General Controls, which represent the baseline requirements for all medical devices. General Controls include requirements for manufacturer registration, device listing, compliance with Quality System Regulations (QSR/GMP), proper labeling, and prohibition of adulteration or misbranding. Most Class I devices are exempt from submitting a premarket notification to the FDA before commercialization.

Class II Devices: Moderate Risk

Class II devices present a moderate level of risk and require more than General Controls to ensure safety and effectiveness. In addition to General Controls, Class II devices must comply with Special Controls. Special Controls are device-specific and may include special labeling requirements, mandatory performance standards, post-market surveillance, and patient registries. The typical regulatory pathway to market for a Class II device is a 510(k) Premarket Notification, through which the manufacturer must demonstrate that the device is "substantially equivalent" to a legally marketed predicate device.

Class III Devices: High Risk

Class III devices present the highest risk. These devices typically support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. General and Special Controls alone are insufficient to guarantee their safety and effectiveness. Therefore, Class III devices require Premarket Approval (PMA). A PMA is a scientific and regulatory review process that requires the manufacturer to submit valid scientific evidence, including data from human clinical trials, to prove the device is safe and effective for its intended use.

---

Purpose of the Investigational Device Exemption (IDE)

Just as drug researchers need an IND to conduct clinical studies, device researchers require an Investigational Device Exemption (IDE) under 21 CFR Part 812 to conduct clinical investigations of unapproved medical devices. An IDE allows an investigational device to be shipped in interstate commerce for clinical research purposes without complying with certain FDA requirements that apply to commercial devices.

Specifically, an approved IDE exempts the investigational device from regulations regarding:

• Premarket Approval (PMA) or 510(k) premarket notification.
• Quality System Regulations (QSR) except for design controls (unless specifically exempted).
• Registration and listing requirements with the FDA.
• Misbranding provisions regarding labeling and promotion (the device must be labeled "Caution - Investigational Device. Limited by Federal law to investigational use").

An IDE is required if a clinical trial is designed to collect safety and effectiveness data on an unapproved device, or a new use of an approved device, to support a future marketing application (such as a PMA or 510(k)).

---

Significant Risk (SR) vs. Non-Significant Risk (NSR) Devices

One of the most critical distinctions in device research is whether an investigational device is classified as a Significant Risk (SR) or a Non-Significant Risk (NSR) device. This classification determines the regulatory pathway, the required approvals, and the administrative burden on the sponsor and investigators.

Under 21 CFR 812.3(m), a Significant Risk Device is defined as an investigational device that:

1. Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject.
2. Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject.
3. Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health, and presents a potential for serious risk to the health, safety, or welfare of a subject.
4. Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

Examples of SR vs. NSR Devices

• Significant Risk (SR) Examples: Pacemakers, coronary stents, artificial hearts, orthopaedic implants (artificial joints), extended-wear contact lenses, surgical lasers, and electroconvulsive therapy (ECT) devices.
• Non-Significant Risk (NSR) Examples: Daily-wear contact lenses, standard dental fillings, external tongue depressors, traditional wound dressings, blood pressure cuffs, and general-use surgical instruments.

---

The Dual Review Pathway and the IRB's Role in NSR

The regulatory review pathway for clinical investigations of medical devices differs significantly from drugs, primarily due to the active role of the Institutional Review Board (IRB) in device risk determination.

The Sponsor's Initial Assessment

The sponsor of the device study is responsible for making the initial determination of whether the device is SR or NSR. The sponsor must present this assessment, along with a written justification, to the reviewing IRB.

The IRB's Critical Role

The IRB serves as the primary evaluator of the device's risk. The IRB must independently review the sponsor's SR/NSR determination. The IRB cannot simply accept the sponsor's classification; it must perform its own evaluation based on the protocol, the device description, and proposed clinical procedures.

• If the IRB agrees the device is NSR: The study can proceed immediately under the abbreviated IDE requirements of 21 CFR 812.2(b). An abbreviated IDE does not require a formal application to the FDA. The sponsor must comply with basic record-keeping, labeling, and monitoring requirements, but does not need to wait for FDA clearance. The study can begin as soon as the IRB grants approval.
• If the IRB determines the device is SR (or disagrees with the sponsor's NSR claim): The sponsor must notify the FDA and submit a full IDE application. The clinical investigation cannot begin until the sponsor receives both IRB approval AND FDA approval of the IDE.

The FDA is the ultimate authority on device risk determination. If the FDA determines a device is SR, the sponsor must submit an IDE, even if an IRB previously approved the study as NSR.

---

Adverse Event Reporting: Unanticipated Adverse Device Effects (UADEs)

In device trials, safety reporting is centered around the concept of an Unanticipated Adverse Device Effect (UADE). Under 21 CFR 812.3(s), a UADE is defined as:

Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application; or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

The reporting requirements and timelines for UADEs are strict and utilize working days rather than calendar days.

Investigator Reporting Timeline

The investigator must submit a report of a UADE to the sponsor and the reviewing IRB as soon as possible, but in no event later than 10 working days after the investigator first learns of the effect (21 CFR 812.150(a)(1)).

Sponsor Reporting Timeline

The sponsor is responsible for evaluating the UADE and conducting an immediate investigation. The sponsor must report the results of this evaluation to the FDA, all reviewing IRBs, and all participating investigators within 10 working days after the sponsor first receives notice of the effect (21 CFR 812.150(b)(1)).

If the sponsor determines that a UADE presents an unreasonable risk to subjects, the sponsor must immediately terminate all investigations or the parts of the investigations presenting that risk. Termination must occur no later than 5 working days after the sponsor makes this determination and no later than 15 working days after first receiving notice of the effect.

Form FDA 3500A

For device studies, serious adverse events and UADEs are documented and reported using Form FDA 3500A. This is the mandatory reporting form for investigational device adverse events, compared to Form FDA 3500 which is used for voluntary reporting by clinicians in post-marketing surveillance.